DAX25.612 +0,6%Est506.344 +1,5%MSCI World4.343 -0,1%Top 10 Crypto8,3300 +0,9%Nas25.087 +2,6%Bitcoin56.037 +0,5%Euro1,1533 +0,7%Öl89,44 -1,4%Gold4.099 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Microsoft 870747 adidas A1EWWW Rheinmetall 703000 SAP 716460 Infineon 623100 Siemens Energy ENER6Y SpaceX A42D4F NVIDIA 918422 Micron Technology 869020 Deutsche Telekom 555750 Deutsche Bank 514000 Meta Platforms (ex Facebook) A1JWVX Volkswagen (VW) vz. 766403 BASF BASF11 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Bilanzflut: DAX letztlich stärker -- US-Börsen ziehen an -- BMW mit Gewinnrückgang -- adidas-Ergebnisentwicklung ausgebremst -- Microsoft überzeugt -- SpaceX, Meta, NVIDIA, AMD, Micron im Fokus
Top News
Aktueller Marktbericht zum Goldpreis, Ölpreis, Silberpreis und Erdgaspreis Aktueller Marktbericht zum Goldpreis, Ölpreis, Silberpreis und Erdgaspreis
Aktien von SAP, Salesforce und Co. kräftig im Minus: Anleger kehren zu Chip-Aktien zurück Aktien von SAP, Salesforce und Co. kräftig im Minus: Anleger kehren zu Chip-Aktien zurück
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Akebia Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
1,12 EUR +0,02 EUR +1,64 %
STU
1,34 USD +0,07 USD +5,12 %
BTT
finanzen.net zero
Akebia Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.297,52 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1XF0S

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00972D1054

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAKBA

Akebia Therapeutics Aktien News

DatumMeistgelesen
PR NewswireQ32 Bio Sells Complement Inhibitor ADX-097
PR NewswireAkebia Therapeutics Announces Multiple Positive Business Updates
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wer­bungAkebia Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireAkebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireU.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
PR NewswireAkebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
PR NewswireVadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
PR NewswireAkebia Therapeutics to Present at the Jefferies London Healthcare Conference
PR NewswireAkebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
PR NewswireAkebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
PR NewswireCMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
PR NewswireAkebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at Upcoming Investor Conferences
PR NewswireAkebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at Upcoming Investor Conferences
PR NewswireAkebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
PR NewswireAkebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the Jefferies Global Healthcare Conference
PR NewswireAkebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
PR NewswireAkebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
PR NewswireAkebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Secures $55 Million Term Loan Financing

Akebia Therapeutics News

Akebia Therapeutics News: auf dieser Seite finden Sie alle Akebia Therapeutics News und Nachrichten zur Akebia Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Akebia Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Akebia Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.